“Cialis Challenge”: Initial Results Indicate Patients Prefer Lilly/Icos Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The joint venture is pleased with the early response to its sampling program; the “overwhelming majority” of 10,000 vouchers have been redeemed for Cialis, rather than for competing erectile dysfunction therapies Levitra and Viagra.
You may also be interested in...
King/Mylan Merger Will Provide Critical Mass To Develop Palatin's ED Agent
King will pay up to $250 mil. to in-license the Phase II agent PT-141 for female sexual dysfunction and erectile dysfunction. King says the melanocortin receptor agonist will provide better safety and efficacy compared to the currently marketed PDE-5 inhibitors.
King/Mylan Merger Will Provide Critical Mass To Develop Palatin's ED Agent
King will pay up to $250 mil. to in-license the Phase II agent PT-141 for female sexual dysfunction and erectile dysfunction. King says the melanocortin receptor agonist will provide better safety and efficacy compared to the currently marketed PDE-5 inhibitors.
"Cialis Challenge": 20% Of Patients Redeem Vouchers For Viagra, Levitra
Lilly/Icos reports that 80% of 22,000 vouchers issued under the sampling program have been used to purchase more Cialis. The erectile dysfunction drug has captured approximately 16% of total Rx in the PDE-5 inhibitor class.